Additionally, as a part of subsequent therapy for locally advanced/metastatic disease or if the patient has recurrent disease, Adagrasib or Sotorasib may be used (if the patient is positive for KRAS G12C mutation) [27,28]. Here, KRAS is linked to metastatic neoplasm.